Alkem Laboratories Ltd. (NSE: ALKEM), a major Indian pharmaceutical player, reported solid unaudited financial results for the third quarter ended December 31, 2025. Total revenue from operations grew 10.7% year-over-year (YoY) to Rs. 37,368 million, driven by robust international expansion. <\/p>\n\n\n\n
The company also unveiled a binding term sheet for acquiring a majority stake in Switzerland-based Occlutech Holding AG, a global leader in minimally invasive cardiac implants, via subsidiary Alkem MedTech Pvt Ltd.<\/p>\n\n\n\n
Earnings before interest, tax, depreciation, and amortization (EBITDA) reached Rs. 8,280 million, up 9.0% YoY, with margins steady at 22.2% versus 22.5% in Q3 FY25. Profit before tax (after exceptional items) rose 6.9% to Rs. 7,812 million. Net profit after non-controlling interest increased 1.6% to Rs. 6,360 million.<\/p>\n\n\n\n
An exceptional item of Rs. 528 million stemmed from the Indian government’s notification on four Labour Codes. Research and development expenses rose to Rs. 1,390 million (3.7% of revenue) from Rs. 1,312 million (3.9%) YoY, underscoring innovation focus.<\/p>\n\n\n\n
According to IQVIA (SSA) data, Alkem grew 9.8% YoY, slightly trailing the Indian Pharmaceutical Market (IPM) at 10.9%. It outperformed in acute (8.6% vs. IPM 7.8%) and chronic segments (15.8% vs. IPM 15.6%).<\/p>\n\n\n\n
India sales hit Rs. 24,959 million, up 5.5% YoY, comprising 67.2% of total revenue (down from 71.1%). Alkem outpaced IPM in six therapies: anti-infectives (~1.4x), VMN (~2.0x), pain (~1.4x), anti-diabetic (~1.2x), respiratory (~1.2x), and derma (~1.8x). This reflects resilient execution in a competitive market.<\/p>\n\n\n\n
International sales jumped 26.6% YoY to Rs. 12,157 million, accounting for 32.6% of total revenue. US sales grew 18.8% to Rs. 7,533 million (20.3% of total), while non-US sales soared 41.6% to Rs. 4,624 million (12.5% of total).<\/p>\n\n\n\n
In the US, Alkem filed two Abbreviated New Drug Applications (ANDAs) and secured seven approvals during the quarter. As of December 31, 2025, it had filed 188 ANDAs, two New Drug Applications (NDAs), and one Biologics License Application (BLA), with 167 ANDA approvals (including 20 tentative).<\/p>\n\n\n\n
The proposed majority stake in Occlutech marks a pivotal medtech entry. As the third-largest global player in minimally invasive cardiac implants, Occlutech offers strong R&D, manufacturing, and presence in high-barrier markets. <\/p>\n\n\n\n
Sandeep Singh, Managing Director, noted: \u201cThis acquisition holds strategic importance as we work towards establishing a global footprint in medical devices. Occlutech provides a strong lever for Alkem MedTech to expand into cardiovascular along with orthopaedics. Medtech is a natural extension for Alkem. In the company years, along with Enzene Biosciences, our Biotech arm, we expect Alkem MedTech to become meaningful growth pillar for the company.\u201d<\/p>\n\n\n\n
Dr. Vikas Gupta, CEO, remarked: \u201cIn Q3, we delivered a stable performance in a dynamic operating environment, supported by strong fundamentals in our domestic business and consistent execution across our international businesses. We remain bullish on the growth opportunities in domestic as well as international business and are on track to deliver our full year guidance. Looking ahead, the planned launch of our GLP-1 semaglutide in March 2026 is expected to be among our key growth drivers. Our focus remains on execution, strengthening our product portfolio, and building long-term competitiveness across markets.\u201d<\/p>\n\n\n\n
Alkem’s balanced growth across domestic and export markets, coupled with medtech diversification, positions it for sustained momentum in FY26.<\/p>\n\n\n\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
Alkem Laboratories Ltd. (NSE: ALKEM), a major Indian pharmaceutical player, reported solid unaudited financial results for the third quarter ended December 31, 2025. Total revenue from operations grew 10.7% year-over-year (YoY) to Rs. 37,368 million, driven by robust international expansion. The company also unveiled a binding term sheet for acquiring a majority stake in Switzerland-based […]<\/p>\n","protected":false},"author":2388,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941,392,5],"tags":[12565,10162],"class_list":["post-180788","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","category-earnings","category-latest","tag-generic-formulation","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":140922,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-ltd-nse-alkem-q3-fy23-results-out-total-income-rises-15-yoy\/","url_meta":{"origin":180788,"position":0},"title":"Alkem Laboratories Ltd. (NSE: ALKEM): Q3 FY23 Results Out; Total Income Rises 15% YoY","author":"Divyansh_Kasana","date":"February 10, 2023","format":false,"excerpt":"Alkem Laboratories Ltd.(NSE:ALKEM) is a pharmaceutical company that specializes in developing, manufacturing, and marketing of pharmaceutical and nutraceutical products. The company operates in both the domestic and international markets. It offers a wide range of products in various therapeutic segments such as cardiology, gastroenterology, neurology, orthopedics, and more. Alkem Laboratories\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/bb3df30c-f366-48d9-a0f1-d7a6be8c4ba8.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/bb3df30c-f366-48d9-a0f1-d7a6be8c4ba8.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/bb3df30c-f366-48d9-a0f1-d7a6be8c4ba8.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/bb3df30c-f366-48d9-a0f1-d7a6be8c4ba8.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/bb3df30c-f366-48d9-a0f1-d7a6be8c4ba8.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/bb3df30c-f366-48d9-a0f1-d7a6be8c4ba8.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":142492,"url":"https:\/\/alphastreet.com\/india\/earnings-alkem-laboratories-ltd-nsealkem-q3fy23-results-out-total-income-rise-15-yoy\/","url_meta":{"origin":180788,"position":1},"title":"Earnings | Alkem Laboratories Ltd.(NSE:ALKEM): Q3FY23 Results Out; Total Income rise 15% YoY","author":"Divyansh_Kasana","date":"February 22, 2023","format":false,"excerpt":"Alkem Laboratories Ltd.(NSE:ALKEM) is a pharmaceutical company based in India that specializes in the manufacturing and marketing of generic and branded drugs, including formulations, active pharmaceutical ingredients (APIs), and nutraceuticals. The company was founded in 1973 and has since grown into one of the top pharmaceutical companies in India, with\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":170582,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-q1-fy26-earnings-results\/","url_meta":{"origin":180788,"position":2},"title":"Alkem Laboratories Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Alkem Laboratories Ltd is a global pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b93,371 crore, up 11.18% year-on-year (YoY) from \u20b93,032 crore in Q1 FY25. Total Expenses: \u20b92,750 crore, up 8.61%\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"ALKEM Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172398,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-q2-fy26-earnings-results\/","url_meta":{"origin":180788,"position":3},"title":"Alkem Laboratories Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 14, 2025","format":false,"excerpt":"Alkem Laboratories, engaged in the pharmaceutical and nutraceutical business with global operations, reported steady financial results for Q2FY26. Financial Highlights: Revenues increased 17.16% year-on-year to \u20b94,001 crore from \u20b93,415 crore. Total expenses rose 15.89% to \u20b93,209 crore from \u20b92,769 crore. Consolidated net profit grew 10.97% to \u20b9779 crore from \u20b9702\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/A-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/A-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/A-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/A-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/A-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/A-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":165768,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-ltd-q2fy25-14-rise-in-profits\/","url_meta":{"origin":180788,"position":4},"title":"Alkem Laboratories Ltd Q2FY25; 14% rise in Profits","author":"Divyansh_Kasana","date":"November 21, 2024","format":false,"excerpt":"Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107) Financial Results: Alkem Laboratories Ltd reported Revenues for Q2FY25 of \u20b93,415.00 Crores down from \u20b93,440.00 Crore year on year,\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/11\/FG.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/11\/FG.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/11\/FG.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/11\/FG.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/11\/FG.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/11\/FG.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168663,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-ltd-q4fy25-6-rise-in-profits\/","url_meta":{"origin":180788,"position":5},"title":"Alkem Laboratories Ltd Q4FY25; 6% rise in Profits","author":"Divyansh_Kasana","date":"June 5, 2025","format":false,"excerpt":"Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107) Financial Results: Alkem Laboratories Ltd reported Revenues for Q4FY25 of \u20b93,144.00 Crores up from \u20b92,936.00 Crore year on year,\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/06\/I-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180788","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2388"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=180788"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180788\/revisions"}],"predecessor-version":[{"id":180791,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180788\/revisions\/180791"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=180788"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=180788"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=180788"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}